These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

57 related articles for article (PubMed ID: 20015973)

  • 1. Nicotine-patch therapy on mucocutaneous lesions of Behcet's disease: a case series.
    Ciancio G; Colina M; La Corte R; Lo Monaco A; De Leonardis F; Trotta F; Govoni M
    Rheumatology (Oxford); 2010 Mar; 49(3):501-4. PubMed ID: 20015973
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fas (CD95) and bcl-2 expression in active skin lesions of Behçet's disease.
    Bariş YS; Yildiz L; Sentürk N; Kandemir B
    J Eur Acad Dermatol Venereol; 2005 Sep; 19(5):569-72. PubMed ID: 16164710
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediction of abstinence at 10 weeks based on smoking status at 2 weeks during a quit attempt: secondary analysis of two parallel, 10-week, randomized, double-blind, placebo-controlled clinical trials of 21-mg nicotine patch in adult smokers.
    Ferguson SG; Gitchell JG; Shiffman S; Sembower MA
    Clin Ther; 2009 Sep; 31(9):1957-65. PubMed ID: 19843485
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Smoking cessation: a clinical study of the transdermal nicotine patch.
    Smith TM; Winters FD
    J Am Osteopath Assoc; 1995 Nov; 95(11):655-6, 661-2. PubMed ID: 8575948
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and effectiveness of transdermal nicotine patch in smokers admitted with acute coronary syndromes.
    Meine TJ; Patel MR; Washam JB; Pappas PA; Jollis JG
    Am J Cardiol; 2005 Apr; 95(8):976-8. PubMed ID: 15820167
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nicotine patches for aphthous ulcers due to Behçet's syndrome.
    Scheid P; Bohadana A; Martinet Y
    N Engl J Med; 2000 Dec; 343(24):1816-7. PubMed ID: 11185607
    [No Abstract]   [Full Text] [Related]  

  • 7. Antitumor necrosis factor-alpha therapy for early postoperative recurrence of gastrointestinal Behçet's disease: report of a case.
    Byeon JS; Choi EK; Heo NY; Hong SC; Myung SJ; Yang SK; Kim JH; Song JK; Yoo B; Yu CS
    Dis Colon Rectum; 2007 May; 50(5):672-6. PubMed ID: 17216141
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized trial of nortriptyline combined with transdermal nicotine for smoking cessation.
    Prochazka AV; Kick S; Steinbrunn C; Miyoshi T; Fryer GE
    Arch Intern Med; 2004 Nov; 164(20):2229-33. PubMed ID: 15534159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Which smokers are helped to give up smoking using transdermal nicotine patches? Results from a randomized, double-blind, placebo-controlled trial.
    Yudkin PL; Jones L; Lancaster T; Fowler GH
    Br J Gen Pract; 1996 Mar; 46(404):145-8. PubMed ID: 8731618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [A double-blind trial of nicotine patches in smoking cessation].
    Tønnesen P; Nørregaard J; Simonsen K; Säwe U
    Ugeskr Laeger; 1992 Jan; 154(5):251-4. PubMed ID: 1736456
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rate of nicotine onset from nicotine replacement therapy and acute responses in smokers.
    Perkins KA; Lerman C; Keenan J; Fonte C; Coddington S
    Nicotine Tob Res; 2004 Jun; 6(3):501-7. PubMed ID: 15203784
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of a 16-hour transdermal nicotine patch in a medical practice setting, without intensive group counseling.
    Sachs DP; Säwe U; Leischow SJ
    Arch Intern Med; 1993 Aug; 153(16):1881-90. PubMed ID: 8110249
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Precessation treatment with nicotine patch significantly increases abstinence rates relative to conventional treatment.
    Rose JE; Herskovic JE; Behm FM; Westman EC
    Nicotine Tob Res; 2009 Sep; 11(9):1067-75. PubMed ID: 19567826
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Behçet's disease in Lebanon: report of 100 cases.
    Ghayad E; Tohme A
    J Med Liban; 1995; 43(1):2-7. PubMed ID: 8676358
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The smoking cessation efficacy of varying doses of nicotine patch delivery systems 4 to 5 years post-quit day.
    Daughton DM; Fortmann SP; Glover ED; Hatsukami DK; Heatley SA; Lichtenstein E; Repsher L; Millatmal T; Killen JD; Nowak RT; Ullrich F; Patil KD; Rennard SI
    Prev Med; 1999 Feb; 28(2):113-8. PubMed ID: 10048102
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Thalidomide in the treatment of aphthosis and Behçet's disease. 4 years' experience].
    Torras H; Lecha M; Mascaró/ JM
    Med Cutan Ibero Lat Am; 1982; 10(2):103-112. PubMed ID: 6759802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined use of nicotine patch and gum in smoking cessation: a placebo-controlled clinical trial.
    Kornitzer M; Boutsen M; Dramaix M; Thijs J; Gustavsson G
    Prev Med; 1995 Jan; 24(1):41-7. PubMed ID: 7740014
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of different nicotine replacement therapies on postcessation psychological responses.
    Strasser AA; Kaufmann V; Jepson C; Perkins KA; Pickworth WB; Wileyto EP; Rukstalis M; Audrain-McGovern J; Lerman C
    Addict Behav; 2005 Jan; 30(1):9-17. PubMed ID: 15561445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effectiveness of nicotine-patch therapy for smoking cessation in patients with schizophrenia.
    Chou KR; Chen R; Lee JF; Ku CH; Lu RB
    Int J Nurs Stud; 2004 Mar; 41(3):321-30. PubMed ID: 14967189
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of high-dose nicotine patch on the characteristics of lapse episodes.
    Ferguson SG; Shiffman S
    Health Psychol; 2010 Jul; 29(4):358-66. PubMed ID: 20658822
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.